Boston Scientific has received CE mark approval for use of its Vercise Deep Brain Stimulation (DBS) System in the treatment of Parkinson’s disease.
According to the company, the Vercise DBS System is the first and only commercially available DBS system to incorporate multiple independent current control, which is designed to selectively stimulate targeted areas in the brain, providing physicians fine control of stimulation and minimising side effects of stimulation for the patient. In addition, the system offers the longest battery life available for DBS therapy.
The first commercial implant of the Vercise DBS System was performed by Cordula Matthies, head of Functional Neurosurgery and Jens Volkmann, director of the Department of Neurology at the University Clinic Wurzburg in Germany.
“We welcome the Vercise DBS System,” said Volkmann. “We believe it represents advancement in DBS technology through flexible and unique programming options. We believe the system gives neurologists the ability to precisely target stimulation based on patient needs.”
“The unique technology offered by the Vercise DBS System provides us with new stimulation options we have never had before,” said Matthies. “I look forward to seeing a positive impact in patients’ quality of life.”
